AXT's Q1 Loss Narrows, Revenue Tops Estimates, but Core Permit and Dilution Risks Persist

What happened

AXT reported a Q1 loss of $0.01 per share, beating the consensus estimate of a $0.04 loss, and revenue exceeded expectations. The better-than-expected results reflect some improvement in shipment cadence, but the DeepValue report highlights that export permit constraints remain the binding factor, with North America revenue still negligible. The company is pursuing a capacity expansion funded by a massive equity raise, which dilutes existing shareholders and increases the penalty for any delays in permit normalization. Inventory remains elevated at $81.7M net, and the risk of additional reserves or a $49M Tongmei redemption obligation adds downside pressure. Until Q2 results demonstrate sustained sequential revenue growth and gross margin recovery toward 20%, the risk/reward skews negative.

Implication

The narrower loss and revenue beat provide some near-term relief, but the core thesis from the DeepValue report remains intact: permit uncertainty, dilution from the April equity raise, and high inventory levels limit upside. For long-term investors, the risk/reward is unattractive until the company demonstrates two consecutive quarters of permit-driven revenue growth and gross margin improvement above 20%. The current valuation at $70.2, with a market cap over $3B on negative earnings, leaves little room for error. Consider trimming into strength or waiting for a better entry near $45.

Thesis delta

Q1 results modestly beat low expectations, but do not shift the thesis. The binding constraint—export permit cadence—remains unresolved, and the massive equity raise increases the stakes. The thesis remains a potential sell, with the need for operational proof in Q2.